Hereditary Cancer Risk • Comprehensive 32-Gene PanelPANEL-CGX-32

Hereditary Cancer Risk Screening (CGx)

The Hereditary Cancer Screening Panel evaluates high-penetrance and moderate-risk genetic variants associated with inherited cancer syndromes. By analyzing 30+ critical tumor-suppressor genes and DNA mismatch repair pathways, this panel enables proactive surveillance, early-stage detection, and personalized prophylactic strategies for patients and their families.

Genes Evaluated32 Genes

Analytical Accuracy99.9%

Turnaround Time7–10 Days

Specimen Collection5-Min Swab

Check If You Qualify

Takes under 2 minutes • Quick Pre-Qualification

Check Eligibility →

HIPAA 256-Bit Encrypted

Who Should Consider This Screening?

Healthcare providers recommend this diagnostic panel for individuals with the following personal or family health indicators:

Personal diagnosis of breast, ovarian, colorectal, or pancreatic cancer at any age.

Two or more close blood relatives (parents, siblings, children) diagnosed with cancer.

Family member diagnosed with a known hereditary pathogenic gene mutation (e.g., BRCA1/2).

Male breast cancer in family lineage.

Early-onset cancer diagnosis in immediate family members (<50 years of age).

Multiple primary cancers diagnosed in the same individual.

Biomarkers & Genes Evaluated in this Panel

Processed using high-complexity Next-Generation Sequencing (NGS) in CLIA-certified and CAP-accredited partner laboratories.

Gene Symbol / Name	Clinical Significance	Actionable Impact
BRCA1 / BRCA2Breast Cancer Type 1 & 2 Susceptibility	High-penetrance variants linked to hereditary breast, ovarian, prostate, and pancreatic cancer.	Informs enhanced mammography/MRI schedules, early PSA screening, and targeted PARP inhibitor therapy suitability.
MLH1, MSH2, MSH6, PMS2DNA Mismatch Repair Lynch Syndrome Panel	Associated with elevated risk of colorectal, endometrial, ovarian, and gastrointestinal malignancies.	Guides accelerated colonoscopy frequency (every 1–2 years) starting at earlier clinical ages.
TP53 & PTENLi-Fraumeni & Cowden Syndrome Regulators	Critical tumor suppressor genes governing cellular apoptosis and cell-cycle checkpoint control.	Directs whole-body MRI protocols and proactive multi-organ clinical surveillance.
PALB2 & CHEK2Partner and Localizer of BRCA2 / Checkpoint Kinase 2	Moderate-to-high risk modifiers for breast, prostate, and digestive tract neoplasms.	Supports personalized clinical risk stratification when multi-generational family history is present.

Sample Report & Diagnostic Action Plan

Every patient receives an easy-to-understand diagnostic summary and a detailed clinical report tailored for their primary care doctor.

Sample Result ClassificationPathogenic Variant Identified

Identified Finding:

Pathogenic heterozygous variant identified in BRCA2 (c.5946delT, p.Ser1982fs).

Clinician Recommendation:

Recommend referral to genetic counselor, enhanced annual breast MRI alternating with mammography, and early prostate/pancreatic screening discussion with PCP.

Clinical Care & Laboratory Standards

How our licensed physician network and accredited laboratories deliver personalized diagnostic clarity to your doorstep:

100% Physician-Ordered & CLIA Lab Certified

Physician-ordered hereditary cancer screening evaluates high-penetrance mutations across 30+ critical tumor-suppressor genes. Processed in CAP/CLIA-accredited laboratories to deliver clear, actionable surveillance protocols for patients and their clinical providers.

Our network of state-licensed physicians reviews your clinical indications to confirm medical necessity and coordinate care before any kit is mailed.

Physician-Ordered Clinical Screening

Ready to Check Your Eligibility for Hereditary Cancer Risk Screening (CGx)?

Takes under 2 minutes • Painless at-home cheek swab • 100% Physician Reviewed

Start 2-Minute Pre-Qualification →